In 2023, Amicus Therapeutics completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).
However, Amicus Therapeutics has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2023 |
|---|---|
Total Scope 1 | 0a |
Total Scope 2 | |
Unspecified Calculation Method | 0a |
Total Scope 3 | N/A |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 0a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
No operational GHG emissions data disclosed for Amicus Therapeutics in 2023.
In 2023, the total Scope 1 emissions of Amicus Therapeutics were 0 metric tons of CO₂ equivalent (tCO₂e).a
In 2023, Amicus Therapeutics reported Scope 2 greenhouse gas (GHG) emissions of 0 tCO₂e without specifying the calculation method.a
In 2023, Amicus Therapeutics reported its Scope 2 emissions using an unspecified methodology.a